BC
ACRS icon

Broadfin Capital’s Aclaris Therapeutics ACRS Stock Holding History

Broadfin Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$3.57M Buy
1,888,039
+268,039
+17% +$444K 0.48% 36
2019
Q3 		$1.75M Buy
+1,620,000
New +$2.3M 0.32% 41
2019
Q2 		– Sell
-2,030,925
Closed -$12.2M – 40
2019
Q1 		$12.2M Buy
2,030,925
+153,423
+8% +$1.02M 2.51% 14
2018
Q4 		$13.9M Buy
+1,877,502
New +$19.4M 1.82% 16

Other funds holding ACRS

MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Broadfin Capital's ACRS Position: Q4 2019 in Review

Broadfin Capital increased its Aclaris Therapeutics (ACRS) stake by 17% in Q4 2019, buying an estimated $444K and bringing the position to 1,888,039 shares worth $3.57M. The position accounts for 0.48% of the portfolio, ranked #36.

Broadfin Capital first reported a position in ACRS in Q4 2018 and has held it in 4 quarters since. The position peaked at $13.9M in Q4 2018. 79 funds tracked by Wall St. Rank hold ACRS as of Q4 2019.

  • Broadfin Capital held 1,888,039 shares of Aclaris Therapeutics worth $3.57M as of Q4 2019.
  • Broadfin Capital bought 268,039 Aclaris Therapeutics shares in Q4 2019, an estimated $444K.
  • Aclaris Therapeutics made up 0.48% of Broadfin Capital's portfolio in Q4 2019, its #36 holding.
  • Broadfin Capital first reported a position in Aclaris Therapeutics in Q4 2018 and has held it in 4 quarters since.
  • Broadfin Capital's Aclaris Therapeutics position peaked at $13.9M in Q4 2018.
  • 79 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.